These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Quick Read Bristol Myers Squibb (BMY) reported Q4 2025 non-GAAP EPS of $1.26, missing consensus by 22.7% due to a $1.39B acquired IPRD charge, while legacy drugs Revlimid and Sprycel fell 55% and 60% respectively with generic pomalidomide entry expected in Q1 2026. FedEx (FDX) beat Q2 FY2026 adjusted EPS estimates by over 17% at $4.82 with a planned Freight spin-off targeted for June 1, 2026, and raised full-year guidance to $17.80-$19.00 adjus…